|
C2ORF86 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.73834296851783E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.49560364093304E-11 |
| Normal-vs-Stage2 |
3.66459995682078E-09 |
| Normal-vs-Stage3 |
2.84328116606503E-13 |
| Normal-vs-Stage4 |
1.89093185554157E-12 |
| Stage1-vs-Stage2 |
9.144200E-01 |
| Stage1-vs-Stage3 |
8.230100E-02 |
| Stage1-vs-Stage4 |
5.481700E-02 |
| Stage2-vs-Stage3 |
2.754000E-01 |
| Stage2-vs-Stage4 |
1.514960E-01 |
| Stage3-vs-Stage4 |
5.406200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.63562563072173E-13 |
| Normal-vs-AfricanAmerican |
2.398400E-04 |
| Normal-vs-Asian |
1.28269950216975E-10 |
| Caucasian-vs-AfricanAmerican |
3.648200E-02 |
| Caucasian-vs-Asian |
8.558800E-01 |
| AfricanAmerican-vs-Asian |
1.118360E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.47815134868779E-13 |
| Normal-vs-Female |
4.96380714309907E-12 |
| Male-vs-Female |
2.583800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.04689606878128E-11 |
| Normal-vs-Age(41-60Yrs) |
2.83317813654094E-12 |
| Normal-vs-Age(61-80Yrs) |
8.17235168426578E-13 |
| Normal-vs-Age(81-100Yrs) |
1.176130E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.926800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.386180E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.795600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.301600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.094200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.925600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.620650E-03 |
| Classical-VS-Follicular |
6.852400E-01 |
| Classical-VS-Other |
4.921200E-01 |
| Classical-VS-Normal |
6.19839735094274E-11 |
| Tall-VS-Follicular |
2.203700E-02 |
| Tall-VS-Other |
4.892400E-01 |
| Tall-VS-Normal |
9.47020240005259E-14 |
| Follicular-VS-Other |
6.285200E-01 |
| Follicular-VS-Normal |
9.63706892065375E-12 |
| Other-VS-Normal |
8.375900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.46545014906496E-12 |
| Normal-vs-N1 |
1.44451117733979E-12 |
| N0-vs-N1 |
2.428000E-01 |
|
|
